Pacific Biosciences (PACB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 385,948 | 209,587 | 354,134 | 325,389 | 304,733 |
| Marketable Securities | 382,141 | 620,575 | 521,058 | 447,229 | 529,907 |
| Receivables | 30,486 | 24,034 | 29,589 | 18,786 | 22,756 |
| Inventories | 68,256 | 67,608 | 61,955 | 50,381 | 43,495 |
| TOTAL | $882,297 | $935,552 | $981,111 | $852,074 | $913,896 |
| Non-Current Assets | |||||
| PPE Net | 40,340 | 40,317 | 40,833 | 41,580 | 39,154 |
| Intangibles | 925,681 | 819,753 | 819,985 | 820,219 | 820,268 |
| Other Non-Current Assets | 50,036 | 52,009 | 54,488 | 53,213 | 45,631 |
| TOTAL | $1,016,057 | $912,079 | $915,306 | $915,012 | $905,053 |
| Total Assets | $1,898,354 | $1,847,631 | $1,896,417 | $1,767,086 | $1,818,949 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 16,106 | 16,512 | 17,390 | 12,028 | 12,853 |
| Accrued Expenses | 34,660 | 27,010 | 19,380 | 32,596 | 24,886 |
| Other current liabilities | 101,363 | 193,661 | 189,020 | 179,327 | 4,609 |
| TOTAL | $183,961 | $271,409 | $265,674 | $263,335 | $81,649 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 22,372 | 24,983 | 30,866 | 30,498 | 30,689 |
| Other Non-Current Liabilities | 945,597 | 929,231 | 936,777 | 939,053 | 1,108,947 |
| TOTAL | $950,650 | $934,223 | $938,626 | $940,847 | $1,110,709 |
| Total Liabilities | $1,134,611 | $1,205,632 | $1,204,300 | $1,204,182 | $1,192,358 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 267,444 | 250,558 | 249,891 | 247,079 | 226,109 |
| Common Shares | 258 | 250 | 250 | 227 | 226 |
| Retained earnings | -1,757,057 | -1,690,188 | -1,620,355 | -1,532,340 | -1,447,956 |
| Other shareholders' equity | -1,840 | -2,686 | -1,924 | -4,765 | -6,260 |
| TOTAL | $763,743 | $641,999 | $692,117 | $562,904 | $626,591 |
| Total Liabilities And Equity | $1,898,354 | $1,847,631 | $1,896,417 | $1,767,086 | $1,818,949 |